The Mechanisms and Significances of Synergistic Effects of Mycophenolic Acid and LPS on IL-1β Secretion by Mononuclear
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02435368|
Recruitment Status : Unknown
Verified April 2015 by Xuechan Huang, The Third Affiliated Hospital of Southern Medical University.
Recruitment status was: Recruiting
First Posted : May 6, 2015
Last Update Posted : May 6, 2015
|Condition or disease||Intervention/treatment|
|Lupus Nephritis||Drug: mycophenolic acid|
Mycophenolate mofetil (MMF), which inhibits T and B lymphocyte proliferation, is widely used to treat a variety of autoimmune diseases, such as systemic lupus erythematosus (SLE) and lupus nephritis (LN). We are the first to show that mycophenolic acid (MPA), the active metabolite of MMF, in association with lipopolysaccharide (LPS), is able to promote the secretion of interleukin (IL)-1β, which contradicts the traditional conception that immunosuppressants inhibit the secretion of inflammatory factors.
In this study, we first determined the effects of MPA in association with LPS on IL-1β production. Then, we explored whether the synergized effect on IL-1β production was mediated through the nuclear factor （NF）-κB pathway that produces more pro-IL-1β, or through the triggering of NLRP3 inflammasome that leads to enhanced activation of caspase-1 and accelerated degradation of pro-IL-1β into mature IL-1β.
This study is not only conducive to clarify the mechanisms, signal transduction pathways and potential clinical significances of IL-1β production in LPS and MPA combined treatment, but also to provide experimental data as well as theoretical rationales for more effective and more logical immunosuppressive protocols.
|Study Type :||Observational|
|Estimated Enrollment :||10 participants|
|Official Title:||The Mechanisms and Significances of Synergistic Effects of Mycophenolic Acid and Lipopolysaccharide on Interleukin-1β Secretion by Mononuclear|
|Study Start Date :||April 2015|
|Estimated Primary Completion Date :||November 2015|
|Estimated Study Completion Date :||March 2016|
- Drug: mycophenolic acid
Monocytes were co-cultured with LPS and/or MPA.After 12 hours, the supernatants were harvested and stored at -80°C for ELISA.Other Name: mycophenolate mofetil
- mean ± SD of percentage of IL-1β production induced by Lipopolysaccharide in associate with MPA in monocytes. [ Time Frame: six months ]
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02435368
|Contact: erwei Sun, doctor||+86 firstname.lastname@example.org|
|Contact: xuechan Huang, doctor||+86 email@example.com|
|Study Director:||erwei Sun, doctor||Third Affiliated Hospital of Southern Medical University|